The benefit of new angiogenesis (bevacizumab and aflibercept) inhibitors for multiple angiomatosis therapy: a case report

Czech version

Authors: Dagmar Brančiková ¹; Lenka Ostřížková ¹; Zdeněk Adam ¹; Tomáš Nebeský ²; Luděk Pour ¹; Zdeněk Král ¹; Jiří Mayer ¹
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice ¹; Klinika radiologie a nukleární medicíny LF MU a FN Brno, pracoviště Bohunice ²
Published in: Vnitř Lék 2017; 63(10): 672-678
Category: Case reports

Overview

Angiomatosis is a term for multiple, gradually proliferating hemangiomas (angiodysplasia), affecting multiple organs or tissues at the same time. We describe a 12-year course of treatment of a patient with multiple hemangiomas located in the abdomen, retroperitoneum, oesophagus, mediastinum and also in vertebrae. The diagnosis was made in 2005 within probatory laparotomy, at the age of 28 years. The treatment was commenced right after making the diagnosis with interferon α. Due to its adverse effects (fatigue, anorexia), the use of interferon α was limited to the first year, after which the interferon dose was gradually being reduced until it was discontinued completely. From 2006 to 2011 the treatment was based on thalidomide and temporarily also on lenalidomide. By the end of the year 2011 the patient was stabilized through the effect of these drugs, without a need of repeated blood transfusions. In 2012 his condition got worse again, which required several transfusions in one month. We tested metronomic administration of cyclophosphamide and further administration of propranolol, however neither of them improved the patient’s situation. Injections of octreotide (Sandostatin 0.1 mg twice a day) helped reduce losses during bleeding into the alimentary tract. Still the patient continued to depend on blood transfusions. Therefore, in 2013, bevacizumab was added to the therapy (7.5 mg/kg in 3-week intervals). This treatment stabilized the patient, it reduced the use of transfusions for a period of 2 years, however after 2 years of a successful therapy with bevacizumab there was disease progression shown on CT imaging and hemorrhagic pleural effusion was also detected. After the treatment of hemorrhagic effusion, early in 2015 we transferred to the administration of aflibercept, at first at the dose of 4 mg/kg in 14-day intervals. Arising of massive proteinuria led to the dose reduction to 2 mg/kg while maintaining 14-day intervals. While receiving this dose, the patient tolerates aflibercept therapy without significant adverse effects. At the time of publication, the patient has been treated with aflibercept for 24 months already, of that for the last ten months he has been fully independent of transfusions. Just before commencement of treatment with aflibercept his conditions required several transfusions in a week. This description demonstrates that the efficiency of individual medications for multiple angiomatosis is always time-limited and newly developed and more efficient drugs are needed to manage the disease. Bevacizumab and aflibercept are beneficial for patients with serious forms of multiple angiomatosis.

Key words:
aflibercept – angiomatosis – angiodysplasia – bevacizumab – hemangiomas

Sources

1. Adam Z, Křikavová L, Krejčí M et al. Léčba mnohočetné angiomatózy postihující skelet, břišní i hrudní dutinu interferonem α, thalidomidem a zoledronatem. Vnitř Lék 2008; 54(6): 553–664.

2. Adam Z, Pour L, Krejčí M et al. Úspěšná léčba angiomatózy thalidomidem a interferonem α. Popis pěti případů a přehled léčby angiomatózy a proliferujících hemangiomů. Vnitř Lék 2010; 56(8): 810–824.

3. Adam Z, Pour L, Matýšková M et al. Markery chronické diseminované intravaskulární koagulace u pacienta se mnohočetnou angiomatosou v průběhu antiangiogenní léčby: interferon α, thalidomid a lenalidomid. Vnitř Lék 2012; 58(2): 145–153.

4. Invernizzi R, Quaglia F, Klersy C et al. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Lancet Haematol 2015; 2(11): e465-e473. Dostupné z DOI: <http://dx.doi.org/10.1016/S2352–3026(15)00195–7>.

5. Boey JP, Hahn U, Sagheer S et al. Thalidomide in angiodysplasia-related bleeding. Intern Med J 2015; 45(9): 972–976. Dostupné z DOI: <http://dx.doi.org/10.1111/imj.12850>.

6. Engelen ET, van Galen KP, Schutgens RE. Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. Haemophilia 2015; 21(4): 419–429. Dostupné z DOI: <http://dx.doi.org/10.1111/hae.12701:

7. Heidt J, Langers AMJ, van der Meer et al. Thalidomide as treatment for digestive angiodysplasias. Nederlands J Med 2006; 64(11): 425–428.

8. Bauditz J. Effective treatment of gastrointestinal bleeding with thalidomide – Chances and limitations. World J Gastroenterol 2016; 22(11): 3158–3164. Dostupné z DOI:

9. Lu L, Payvandi F, Wu L et al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009; 77(2): 78–86. Dostupné z DOI: <http://dx.doi.org/10.1016/j.mvr.2008.08.003>.

10. Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias? Br J Haematol 2009; 146(2): 220–222. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2141.2009.07730.x>.

11. Sumrall A, Fredericks R, Berthold A et al. Lenalidomide stops progression of multifocal epitheloid hemangioendothelioma including intracranial disease. J Neurooncol 2010; 97(2): 275–277. Dostupné z DOI: <http://dx.doi.org/10.1007/s11060–009–0017-z>.

12. Martins NB, Chaput KJ, Stawicki SP et al. Octreotide as an adjunct in the management of arterial gastrointestinal bleeding: Should it be considered in refractory cases of obscure origin? Int J Crit Illn Inj Sci 2017; 7(1): 8–11. Dostupné z DOI: <http://dx.doi.org/10.4103/IJCIIS.IJCIIS_14_17>.

13. Beg S, Ragunath K. Review on gastrointestinal angiodysplasia throughout the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2017; 31(1): 119–125. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bpg.2016.11.004>.

14. Grooteman KV, van Geenen EJ, Drenth JP. Multicentre, open-label, randomised, parallel-group, superiority study to compare the efficacy of octreotide therapy 40 mg monthly versus standard of care in patients with refractory anaemia due to gastrointestinal bleeding from small bowel angiodysplasias: a protocol of the OCEAN trial. BMJ Open 2016; 6(9): e011442. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjopen-2016–011442>.

15. Iannone A, Principi M, Barone M et al. Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients? Clin Res Hepatol Gastroenterol 2016; 40(4): 373–377. Dostupné z DOI: <http://dx.doi.org/10.1016/j.clinre.2016.02.003>.

16. Holleran G, Hall B, Breslin N et al. Long-acting somatostatin analogues provide significant beneficial effect in patients with refractory small bowel angiodysplasia: Results from a proof of concept open label mono-centre trial. United European Gastroenterol J 2016; 4(1): 70–76. Dostupné z DOI: <http://dx.doi.org/10.1177/2050640614559121>.

17. Lakkis Z, Kim S, Delabrousse E et al. Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma. J Hepatol 2013; 58(6): 1254–1257. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jhep.2013.01.043>.

18. Fukushima H, Kudo T, Fuskushima T et al. An infant with life-threatening hemangioma successfully treated with low-dose cyclophosphamide. Pediatr Int 2011; 53(6): 1073–1075. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1442–200X.2011.03452.x>.

19. Wilson MW, Hoehn ME, Haik BG et al. Low-dose cyclophosphamide and interferon alfa 2a for the treatment of capillary hemangioma of the orbit. Ophthalmology 2007; 114(5): 1007–1011.

20. Gottschling S, Schneider G, Meyer S et al. Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide. Pediatr Blood Cancer 2006; 46(2): 239–242.

21. Hurvitz SA, Hurvitz CH, Sloninsky L et al. Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol 2000; 22(6): 527–532.

22. Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C et al. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics 2016; 138(4). pii: e20160353. Dostupné z WWW: <http://pediatrics.aappublications.org/content/138/4/e20160353.long>.

23. Tong S, Xu DP, Liu ZM et al. Evaluation of the efficacy and safety of topical timolol maleate combined with oral propranolol treatment for parotid mixed infantile hemangiomas. Oncol Lett 2016; 12(3): 1806–1810.

24. Ren W, Li S, Gao L et al. Low-dose propranolol for infantile hemangioma of the head and neck: Analysis of 23 consecutive patients. Pediatr Int 2017; 59(2): 213–217. Dostupné z DOI: <http://dx.doi.org/10.1111/ped.13109>.

25. Cavalli R, Novotna V, Buffon RB et al. C. Multiple cutaneous and hepatic infantile hemangiomas having a successful response to propranolol as monotherapy at neonatal period. G Ital Dermatol Venereol 2013; 148(5): 525–530.

26. Oosting SF, van Asselt SJ, Brouwers AH et al. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. J Nucl Med. 2016; 57(8): 1244–1250. Dostupné z DOI: <http://dx.doi.org/10.2967/jnumed.115.167643>.

27. Dupuis-Girod S, Ambrun A, Decullier E et al. ELLIPSE Study: A Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. MAbs 2014; 6(3): 794–799. Dostupné z DOI: <http://dx.doi.org/10.4161/mabs.28025>.

28. Mitchell A, Adams LA, MacQuillan G et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008; 14(2): 210–213. Dostupné z DOI: <http://dx.doi.org/10.1002/lt.21417>.

29. Semeraro F, Russo A, Duse S et al. Retinal angiomatosis and cystoid macular oedema in Cogan’s syndrome. Optom Vis Sci 2011; 88(10): E1262–1236. <http://dx.doi.org/10.1097/OPX.0b013e3182271652>.

30. Joeres S, Heussen FM, Treziak T et al. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 2007; 245(11): 1597–1602.

31. Barré A, Dréanic J, Flaujac C et al. Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann’s thrombasthenia? Haemophilia 2016; 22(4): e347-e348. Dostupné z DOI: <http://dx.doi.org/10.1111/hae.12977>.

32. Marlu R, Barthelon J, Durand A et al. Long-term therapy with bevacizumab in a patient with Glanzmann’s thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions. Am J Gastroenterol 2015; 110(2): 352–353. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2014.391>.

33. Bauditz J. Angiogenesis inhibitors for treatment of angiodysplasia-related gastrointestinal bleeding. Dtsch Med Wochenschr 2009; 134(138): 1893–1896. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0029–1237529>.

34. Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenicdrugs for treatment of gastrointestinal bleeding. World J Gastroenterol 2007; 13(45): 5979–5984.

35. Schmid MK, Bachmann LM, Fäs L et al. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol 2015; 99(2): 141–146. Dostupné z DOI: <http://dx.doi.org/10.1136/bjophthalmol-2014–305149>.

36. Bertoni N, Pereira LMS, Severino FE et al. Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma. BMC Medical Genetics 2016; 17: 4. Dostupné z DOI: <http://dx.doi.org/10.1186/s12881–015–0262–2>.